Substance / Medication

Alteplase

Overview

Active Ingredient
alteplase
RxNorm CUI
8410

Indications

® ® CathfloActivase(Alteplase) is indicated for the restoration of function to central venous access devices as assessed by the ability to withdraw blood.

Labeler: Genentech, Inc.Updated: 2026-01-20T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

DESCRIPTION Cathflo Activase should not be administered to patients with known hypersensitivity to Alteplase or any component of the formulation (see).

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Research Evidence

Published studies and systematic reviews

Sort:
Alteplase versus tenecteplase in acute ischemic stroke with large vessel occlusion: a systematic review and meta-analysis.
El Din Moawad Mostafa Hossam, Serag Ibrahim, Abo Elnaga Ahmed A et al. · Eur J Clin Pharmacol · 2026
PMID: 41546719Meta-Analysis
Recombinant human pro-urokinase vs. alteplase within 4.5 hours of acute ischemic stroke: A systematic review and meta-analysis of randomized controlled trials.
Hashmi Tallal Mushtaq, Shafiq Aimen, Zia Rohma et al. · J Stroke Cerebrovasc Dis · 2025
PMID: 40623511Meta-Analysis
Impact of prior antiplatelet therapy on safety and efficacy of alteplase in acute ischemic stroke: a systematic review and meta-analysis.
Naeem Ahmed, Kelani Hesham, Salamah Hazem Mohamed et al. · Neurol Sci · 2025
PMID: 39985653Meta-AnalysisFull text (PMC)
Reteplase versus alteplase for acute ischemic stroke: Meta-analysis.
Alkhiri Ahmed, Salamatullah Hassan K, Alturki Fahad et al. · Am J Emerg Med · 2025
PMID: 40517710Meta-Analysis
Fibrinogen time course in acute ischemic stroke patients treated with intravenous thrombolysis with alteplase or tenecteplase.
Theodorou Aikaterini, Psychogios Klearchos, Kargiotis Odysseas et al. · Eur Stroke J · 2025
PMID: 40518695Meta-AnalysisFull text (PMC)
A methodological assessment of randomization integrity in alteplase for acute ischemic stroke individual patient data meta-analyses.
Garg Ravi, Torrealba-Acosta Gabriel, Mickenautsch Steffen et al. · PLoS One · 2025
PMID: 40106441Meta-AnalysisFull text (PMC)
Intravenous thrombolysis with tenecteplase versus alteplase in acute ischemic stroke tandem occlusions: a systematic review and meta-analysis of current available literature.
Gonçalves Ocílio Ribeiro, Ferreira Márcio Yuri, de Almeida Monteiro Gabriel et al. · J Thromb Thrombolysis · 2025
PMID: 40082388Meta-Analysis
Tenecteplase versus alteplase in patients with acute ischemic stroke: An updated meta-analysis of randomized controlled trials.
Sheraz Maheen, Asif Nawal, Khan Ariba et al. · J Stroke Cerebrovasc Dis · 2025
PMID: 40157656Meta-Analysis
Risk of intracerebral haemorrhage with tenecteplase versus alteplase in acute ischaemic stroke: a meta-analysis.
Tao Min, Zhang Xiao-Han, Yan Ling-Wan et al. · J Neurol · 2025
PMID: 40208343Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Alteplase (substance)
SNOMED CT
387152000
UMLS CUI
C0032143
RxNorm CUI
8410
Labeler
Genentech, Inc.

Clinical Data

This intervention maps to 10 entities in the Healos knowledge graph.

4
Conditions
3
Biomarkers
2
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.